Judge OKs Glaxo's $75M Settlement Over Alleged Relafen Evergreening
A federal judge has tentatively approved a $75 million settlement agreement between GlaxoSmithKline PLC and a group of consumers and third-party payors who claimed the U.K. drug maker broke antitrust law...To view the full article, register now.
Already a subscriber? Click here to view full article